Share this page!

Johnathan Ebben MD, PhD Profile picture
Twitter logo
Oct 21 • 8 tweets • 51 min read
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 2/4 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
#HER2+ #BreastCancer
✅Localized, early ➡️neoadj tx w chemo + anti-HER2
✅⬆️DFS w T-DM1 for residual disease
✅Future role for T-DXd?

📚We captured @drteplinsky’s discussion in this moment: twitter.com/i/events/15831…
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 3/4 #TumorBoardTuesday
Thursday Case🎀

📷 TBT in an image: Take a 👀at a (simplified) guide to treatment of early stage HER2+, localized #BreastCancer!

We review KATHERINE and use of ADCs to improve OS with residual disease. Is there an evolving role for T-DXd? Image
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates 4/4 #TumorBoardTuesday
Thurs Case🎀

🙏 Anti-HER2+ tx in neoadj setting improves pCR. T-DM1 improves OS when residual disease is present.
🤔 Role for other ADCs or even neoadj setting?

➡️Be sure to join us 11.01.22 when @LeciaSequist presents a case of ALK+ #NSCLC #LungCancer
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates @LeciaSequist Remember #TumorBoardTuesday continues to offer AMA & MOC credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/tbteval
ALL CME 🔗: integrityce.com/tbt

@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates @LeciaSequist @drmaxmano @dradesnoyers @MamMa_mimumemo @ElisaAgostinett @SoniaPernas @gary_lyman @DrTJM_MD @adrianakahnmd @g_mountzios @IdoWolf5 @NicoleKuderer
@Baricorcho @FlaviaJacobs_ @CarmenCriscit @mauricallari @z_veitch @DrGattiMays @E_de_Azambuja @LeandroJonatad1 @OlofssonBagge
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates @LeciaSequist @drmaxmano @dradesnoyers @MamMa_mimumemo @ElisaAgostinett @SoniaPernas @gary_lyman @DrTJM_MD @adrianakahnmd @g_mountzios @IdoWolf5 @NicoleKuderer @Baricorcho @FlaviaJacobs_ @CarmenCriscit @mauricallari @z_veitch @AlisonSvoboda @Icro_Meattini @Mattia_Rediti @kevinpunie @stephaniemwong

@RenoHemonc @JenniferLiMD @ParamMD @JaniceTNBCmets @crisbergerot @martha_carlson @perilonthesea @manjuggm @guildsman @anup_kasi @minaseconomides @ehgkulow @DarcyBurbage @MerryTea @Zainamarba
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates @LeciaSequist @drmaxmano @dradesnoyers @MamMa_mimumemo @ElisaAgostinett @SoniaPernas @gary_lyman @DrTJM_MD @adrianakahnmd @g_mountzios @IdoWolf5 @NicoleKuderer @Baricorcho @FlaviaJacobs_ @CarmenCriscit @EricaMarieRomn1 @NeilVasan @SidYadavMD @maryam_lustberg @JasmineSukumar @DrJNaidoo @DrRBarroso @EthanSokol @UmutDisel @ValsamoA @GoPI3Ks @jberchuck @ValerieTeng @mabelonc @FernandoOnco @oncologician @ravi0273 @antoniomarraMD @EduDFonseca22 @DraAnaCasas @DrJen15 @florencecoussy1
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates @LeciaSequist @drmaxmano @dradesnoyers @MamMa_mimumemo @ElisaAgostinett @SoniaPernas @gary_lyman @DrTJM_MD @adrianakahnmd @g_mountzios @IdoWolf5 @NicoleKuderer @Baricorcho @FlaviaJacobs_ @CarmenCriscit @NeilVasan @SidYadavMD @YAbdouMD @crisonco @naborala @hoperugo @ErikaHamilton9 @FilipaLynce @dradityabardia @DrSGraff @SusanGKomen @HeekeMd @DrHBurstein @stolaney1 @tmprowell @Dr_RShatsky @antonyruggeri @CarmenCalfa @sardesai_sagar @OncoAlert @DrReshmaMahtani @realdrgabriel

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Johnathan Ebben MD, PhD

Johnathan Ebben MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @JohnEbbenMDPhD

Johnathan Ebben MD, PhD Profile picture
Oct 7
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 2/4 #TumorBoardTuesday
Thurs Case🎀
Take🏠
#EGFRm #NSCLC:
✅Wait on NGS- IO +TKI=⬆️tox
✅Osimertinib= ex19, 21m
✅New ADCs, small molecules= future options
✅ Re-bx on prog EGFRm- rule out small cell transformation

📚We captured @n8pennell’s discussion:
twitter.com/i/events/15780…
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 3/4 #TumorBoardTuesday
Thursday Case🎀

📷 #TBT in an image: we’ve summarized some key pts re: EGFRm #NSCLC & emerging data- hope to see more ADCs as 3L options for pts with EGFRm disease in the future! Image
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic @esinghimd @nihardesai7 @NicoGagelmann @drteplinsky @jacobadashek 4/4 #TumorBoardTuesday
Thurs Case🎀

🐟Thanks to @n8pennell for an excellent discussion about the future of #EGFRm directed therapy!

➡️Please be sure to join us in 2 weeks on 10/18/22 when @drteplinsky presents a case of
Early-stage #HER2+ #BreastCancer 😀
Read 7 tweets
Johnathan Ebben MD, PhD Profile picture
Sep 23
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 2/ #TumorBoardTuesday
Thurs Case🎀

Take🏠messages :
PIK3CA mutations in ER+ #mBC
✅PIK3CA mut are common- 20-30% of all #BreastCancer & 40%+ of ER+ #mBC
✅PIK3CAm are present in founder clones!

📚We captured as much of the discussion as we could:
Pt 1 twitter.com/i/events/15719…
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 3/5 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages (Part 2):
✅Alpelisib is a PIK3CA inhib= 5.3 mo ⬆️in PFS
✅Side effect mgmt is key- esp. 💩diarrhea,
🍦hyperglycemia
✅Personalized medicine needs personalized side effect mgmt

Part 2 of our convo twitter.com/i/events/15729…
@TumorBoardTues @maryam_lustberg @JasmineSukumar @MPishvaian @JaniceTNBCmets @drteplinsky @ParamMD 4/5 #TumorBoardTuesday
📷 TBT in an image: Take a look at how PIK3CA inhibitors can be clinically deployed, key side effects to watch out for, and the data that supports their use.

👀Look for more developments in this space and even more, highly specific inhibitors to come. Image
Read 13 tweets
Johnathan Ebben MD, PhD Profile picture
Sep 9
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation 2/3 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:

✅3 agents (pembro, atezo, cempilimab) 👍🏽PD-L1 TPS >50% in 1L
– No head to head ICI comparisons
✅OS BETTER w IO alone vs chemo
✅💰tox huge problem!
📚We captured the convo in this moment:
twitter.com/i/events/15675…
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation 2.5/3 #TumorBoardTuesday
Thurs Case🎀

Key factors to choose ICI (in absence of head to head trials):
- Pt experiences/preferences
- Dosing schedule
- $$$ toxicity

The good news: across 3 separate agents (pembrolizumab, atezolizumab, cemiplimab) OS is BETTER w IO alone vs chemo Image
@TumorBoardTues @NarjustFlorezMD @ShrutiPatelMD @MPishvaian @LatinxOncology @dawood_findakly @LungAssociation @esinghimd @jacobadashek @KinhHoangMD @RenoHemonc @tanyawildes @OncBrothers 3/3
Thurs Case🎀

Thanks for joining us for #TumorBoardTuesday!

Some scheduling notes:
@jane_meisel’s #BRCA case is rescheduled for 12.20.22

➡️Please be sure to join us on 09/20/22 when @maryam_lustberg @JasmineSukumar present a case focused on PIK3CA inhibition in #mBC 😀
Read 8 tweets
Johnathan Ebben MD, PhD Profile picture
Sep 2
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD 1/3 #TumorBoardTuesday
Case🎀

Take🏠messages:
In unresectable stage III #NSCLC:
✅ChemoXRT -> IO is SOC
✅STK11 = ⬇️response to IO, but IO still👍🏼after chemoXRT
✅New IO combos- COAST trial ongoing

📚We captured @HosseinBorghaei’s discussion:
twitter.com/i/events/15648…
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD 2/3 #TumorBoardTuesday
Case🎀

📷 TBT in an image:

We summed it up in a graphic- check out management of unresectable stage III #NSCLC, with updated data from PACIFIC, + exciting data from ongoing COAST trial (evaluating anti-CD73 w ICI; anti-NKG2A w ICI).
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD @esinghimd @LaurenBzak @jacobadashek @VivekSubbiah @BiagioMd @FSkoulidis 3/3 #TumorBoardTuesday
Case🎀

Next: we’ll delve into choosing a checkpoint inhibitor (which one??) in the 1L setting in PD-L1 high #NSCLC, with experts @NarjustFlorezMD & @ShrutiPatelMD taking us through their clinical approach.

Have a great and safe holiday weekend!
Read 6 tweets
Johnathan Ebben MD, PhD Profile picture
Aug 19
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer 2/3 #TumorBoardTuesday
Thurs Case🎀

Take🏠:
✅HER2 LOW= IHC1+ OR IHC2+ w - ISH (67% HR+!)
✅T-DXd= after 1L chemo in HER2 low
✅Careful monitoring for ILD!

📚We captured @hoperugo & @LauraHuppert’s discussion in below:

twitter.com/i/events/15588…

twitter.com/i/events/15601…
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert 2.75/3 #TumorBoardTuesday

Check out this graphic outlining the key role for ADCs in the tx of HER2 low #MBC after prior 1L chemo and endocrine therapy.

Hoping for even more changes in the near future w
DB-06! Image
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert @esinghimd @HemoncUcsf @UICHemOnc @Hopkins_HemOnc @TheFellowOnCall @jacobadashek 3/3 #TumorBoardTuesday
Special thanks to @hoperugo & @laura_huppert. It is a privilege to hear from experts who are re-defining tx for #breastcancer w next gen ADCs!

Join us on August 30 as @HosseinBorghaei discusses the latest in stage III #NSCLC!
Read 7 tweets
Johnathan Ebben MD, PhD Profile picture
Aug 12
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek 2/5 #TumorBoardTuesday
Thursday Case🎀

Take🏠:

✅High risk feat= consider adj tx
✅Sunitinib= FDA ☑️; can be hard to tolerate
✅Pembro= FDA ☑️ w DFS benefit
✅irAE mgmt - gr3+= steroids

📚We captured @brian_rini’s discussion in this moment: twitter.com/i/events/15552…
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek 3/5 #TumorBoardTuesday
Thursday Case🎀

📷 TBT in an image: 👀out a clinical algorithm 📊for adj therapy in #RCC.

Some pearls re: irAE mgmt & addtl info to help choose a patient appropriate adjuvant regimen! Image
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek @esinghimd @PaulCrispenMD @apolo_andrea @AmandaNizamMD 4/5 Thurs Case 🎀
#PostTest Q2️⃣ #CME #TumorBoardTuesday
FREE CME🔗 integrityce.com/tbt
CME eval🔗 integrityce.com/TBTeval

Now that you’ve reviewed- try your hand at #CME:

🤨Which strategy would you use for a pt receiving pembrolizumab experiencing #IBD colitis (grade 3)?
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

Send Email!

Email the whole thread instead of just a link!

Separate emails with commas

:(